Proteasome inhibitors in cancer therapy: lessons from the first decade

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The ubiquitin-proteasome pathway regulates intracellular protein turnover, essential for cellular homeostasis.
• Proteasome inhibitors were initially developed as research tools but showed potential as anti-cancer drugs by inducing apoptosis in cancer cells.
• The clinical development of proteasome inhibitors has advanced significantly over the past decade.

Purpose of the Study:

• To review the mechanism of action, clinical efficacy, toxicity, and resistance pathways of proteasome inhibitors.
• To highlight the validation of the ubiquitin-proteasome pathway as a cancer therapeutic target.
• To discuss the development of next-generation proteasome inhibitors.

Main Methods:

• Review of preclinical and clinical studies on proteasome inhibitors.
• Analysis of bortezomib's clinical data in multiple myeloma and mantle cell lymphoma.
• Exploration of resistance mechanisms and strategies for overcoming them.

Main Results:

• Bortezomib, a proteasome inhibitor, is approved for relapsed/refractory multiple myeloma and mantle cell lymphoma, becoming a standard of care.
• Significant progress has been made in understanding proteasome inhibitor mechanisms, efficacy, toxicity, and resistance.
• Lessons from bortezomib are guiding the development of new inhibitors.

Conclusions:

• The ubiquitin-proteasome pathway is a validated target for cancer therapy.
• New proteasome inhibitors show promise for treating bortezomib-resistant and other cancers.
• The development of proteasome inhibitors exemplifies successful translational medicine from bench to bedside.